HiberCell is developing therapeutic agents that target adaptive stress mechanisms in cancer cells, specifically through the inhibition of stress-mitigating pathways and the activation of stress signaling pathways. This approach aims to address treatment resistance, cancer relapse, and metastasis, ultimately enabling patients to achieve longer, cancer-free lives.
Funding
$175.2M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Cancer cells often develop resistance to treatments, leading to relapse and metastasis. A common characteristic of tumors that exhibit these behaviors is the induction of adaptive stress mechanisms.
Solution
HiberCell is developing therapeutic agents designed to target adaptive stress mechanisms in cancer cells. Their approach involves inhibiting stress-mitigating pathways to prevent cancer cell survival and adaptation, activating stress signaling pathways to induce apoptosis, and exploiting stress-induced vulnerabilities in the tumor microenvironment to enhance anti-cancer immune responses. These differentiated treatment strategies aim to overcome treatment resistance, prevent cancer relapse, and inhibit metastasis, ultimately improving patient outcomes. The company's clinical-stage therapeutic candidates include HC-7366, designed to activate the GCN2 kinase, HC-5404, designed to inhibit PERK, and Odetiglucan, which modulates the immune system within the tumor microenvironment.
Target Audience
The primary target audience includes patients with cancers that exhibit treatment resistance, relapse, and metastasis, as well as the oncologists and medical professionals treating these patients.
Features
- HC-7366: A therapeutic candidate designed to activate the General Control Nonderepressible 2 (GCN2) kinase, a key component of the Integrated Stress Response (ISR) signaling pathway.
- HC-5404: A therapeutic candidate designed to inhibit PKR-like Endoplasmic Reticulum Kinase (PERK), which is critical to the function of the Unfolded Protein Response (UPR) signaling pathway.
- Odetiglucan: A systemically administered therapeutic candidate that modulates both the innate and adaptive immune system by binding to a unique combination of receptors on innate immune cells.
- Exploits stress-induced vulnerabilities in the tumor microenvironment to drive a strong anti-cancer immune response.